查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1568351

联网给药设备市场：产业趋势与全球预测（~2035）-依设备类型、连接模式、给药途径、治疗领域和地区

Connected Drug Delivery Devices Market : Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area, and Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 405 Pages | 商品交期: 最快1-2个工作天内

价格

到2024年，连网给药设备的市场规模预计将达到 44亿美元，到2035年的预测期间年复合成长率预计为 10.1%。

不遵守处方药是医疗保健行业的常见问题，导致健康状况恶化（包括慢性病进展和死亡率较高的风险）、住院人数增加以及医疗费用上升。研究表明，大约66%的美国人至少服用一种药物，其中50%的人不按照医生的指示服用。导致药物依从性差的因素包括患者健忘、对相关副作用的认识、难以获得药物、复杂的给药方案以及缺乏适当的医疗保健服务。特别是在美国，每年的医疗保健费用约为 2,900亿美元。人们采用了多种策略来解决这个问题，包括简化用药方案、提供个人化给药方案、病患教育和提供行为支援。

连网药物传输设备是该领域的重要进步。这些是先进的医疗设备，目的是利用数位技术改善药物管理和监测。这些设备包括先进的功能和感测器，并具有无线连接功能（主要是蓝牙、近场通讯、Wi-Fi 和蜂巢式网路），可实现行动应用程式、数位健康平台和电子健康记录的便利连接。这些设备能够即时收集和传输有关患者用药状态、依从性和整体健康状况的资料，实现远端患者监测（实现及时干预）、分析疾病模式（治疗计划）、最佳化患者护理）、共享提醒/向患者发出警报（以确保他们始终遵循用药时间表），增加患者对医疗保健的参与，并减少整体医疗保健支出。

值得注意的是，还开发了各种附加感测器来帮助将传统的药物输送设备转变为先进的设备。由于对准确有效的数位医疗解决方案和技术进步（与远距医疗平台整合）的需求不断增加，预计全球连网药物输送设备市场在未来前景将呈现稳定成长。

本报告调查了全球连网药物传输设备市场，提供了市场概况、设备类型趋势、连接模式、给药途径、治疗领域、地区以及进入市场的公司等资讯。

目录

第1章 前言

第2章 研究方法

第3章 市场动态

第4章 经济与其他专案特定考量

第5章 执行摘要

第6章 简介

第7章 市场情势：互联/智慧给药设备

  • 章节概述
  • 连网/智慧给药设备：市场情势
  • 连网/智慧给药设备製造商：市场情势

第8章 市场情势：附加感测器

  • 章节概述
  • 附加感测器：市场状况
  • 附加感测器製造商：市场状况

第9章 产品竞争力分析

  • 章节概述
  • 假设和主要参数
  • 调查方法
  • 连网给药设备与附加感测器：产品竞争分析

第10章 公司简介：北美连网/智慧给药设备製造商

第11章 公司简介：欧洲连网/智慧给药设备製造商

第12章 公司简介：亚太及其他地区的互联/智慧给药设备製造商

第13章 临床试验分析

第14章 伙伴关係与协作

第15章 融资与投资

  • 章节概述
  • 融资模式
  • 连网/智慧给药设备：融资与投资，2015-2020年
  • 截至2020年的融资与投资摘要
  • 连网/智慧给药设备：融资与投资，2021-2024年

第16章 价值链/成本价格分析

  • 章节概述
  • 连网/智慧给药设备：价值链
  • 整个价值链的成本分配

第17章 连网/智慧给药设备的监管状况

第18章 案例研究：应用连网药物传输设备提高药物依从性

第19章 SWOT 分析

第20章 全球互联给药设备市场

第21章 互联药物传输设备市场（依设备类型）

第22章 互联药物输送设备市场（依连接类型）

第23章 互联药物输送设备市场（依给药途径）

第24章 互联药物传输设备市场（依治疗领域）

第25章 互联药物输送设备市场（依地区）

第26章 结论

第27章 高阶主管洞察力

第28章 附录 1：表格资料

第29章 附录2：公司与组织名单

第30章 附录 3：2015-2020年伙伴关係与合作

Product Code: RA100512

The Connected Drug Delivery Devices Market is valued at USD 4.4 billion in 2024 and is projected to grow at a CAGR of 10.1%, during the forecast period till 2035.

Noncompliance with prescribed medications is a prevalent issue in the healthcare industry, contributing to poor health outcomes (including chronic disease progression and high risk of mortality), increased cases of hospitalization and high healthcare costs. Studies reveal that around 66% of the people in the US are prescribed at least one medicine; of these, 50% are not taken by patients as directed by the physicians. The factors contributing to the non-adherence towards medications include patient forgetfulness, perception of associated side effects, difficulty in accessing medications, complicated dosing schedules and lack of access to adequate healthcare services. Notably, poor adherence to medication regimen poses a substantial financial burden on the healthcare system; specifically in the US, it costs around USD 290 billion annually. In order to address this concern, various strategies are being employed, such as simplifying the dosage regimens, offering personalized medication schedules, educating the patients and providing behavioral support.

Connected drug delivery devices turn out to be a significant advancement in this area. These are characterized as advanced medical devices that are designed to improve drug administration and monitoring, using digital technologies. These devices are embedded with advanced features and sensors, and have wireless connectivity capabilities (primarily facilitated through Bluetooth, near field communication, Wi-Fi or cellular networks), enabling convenient connection to mobile applications, digital health platforms and electronic health records. These devices enable real-time collection and transfer of data related to patients medication usage, compliance and overall health status, allowing remote monitoring of patient (to enable timely interventions), analyzing disease patterns (to optimize treatment plans), sharing reminders / alerts to patients (to follow their dosage schedules consistently), encouraging participation of patients in their health management and reducing the overall healthcare expenditures.

It is noteworthy that various add-on sensors are also being developed that are useful in transforming conventional drug delivery devices into advanced ones. With the growing demand for accurate and effective digital health solutions and advancement in technologies (integration with telehealth platforms), the global connected drug delivery devices market is poised to witness steady growth, in the future outlook.

Key Market Segments

Type of Device

  • Connected / Smart Wearable Injectors
  • Connected / Smart Inhalers
  • Connected / Smart Pen Injectors
  • Connected / Smart Autoinjectors
  • Connected / Smart Needle-free Injection Systems

Mode of Connectivity

  • Bluetooth-enabled Devices
  • Near Field Communication-enabled Devices
  • Cellular-enabled Devices
  • Wide Area Network-enabled Devices

Route of Administration

  • Parenteral
  • Inhalational

Therapeutic Area

  • Metabolic Disorders
  • Respiratory Disorders
  • Autoimmune Disorders
  • Other Disorders

Geographical Regions

  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain and Rest of Europe)
  • Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific)
  • Middle East and North Africa (Egypt, Israel, Argentina and the Rest of the Middle East and North Africa)
  • Latin America and the Rest of the World (Brazil, Argentina and Other Countries)

Research Coverage:

The market report on Connected Drug Delivery Devices covers the following elements:

  • An introduction to medication adherence, highlighting the different digital solutions that enhance a patient's ability to follow their prescribed dosage regimens. The chapter also includes details about the connected / smart drug delivery systems, their different types (based on type of device and technology used), key features and development processes involved. Further, it outlines the regulatory guidelines governing the development and approval of connected / smart drug delivery systems. Furthermore, the chapter also discusses the various advantages and limitations of these systems, as well as the impact of COVID-19 pandemic on this domain.
  • An insightful analysis of the overall connected drug delivery devices market landscape, featuring information on several relevant parameters, such as stage of development (approved / launched and under development), launch year of device, type of integrated device (smart handheld injector, smart wearable injector, smart inhalers, smart pill and others), route of administration (subcutaneous, inhalation, oral, intramuscular, epidural, others), therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, autoimmune disorders, chronic disorders, oncological disorders, cardiovascular disorders, immunological disorders, pain disorders and other disorders), target indication, key features (audio / visual alerts and reminders / notifications), mode of connectivity (Bluetooth, USB, internet connectivity, near field communication), availability of companion mobile application and availability of data storage / cloud platform. In addition, it also encompasses tabulated information on regulatory approvals, geographical reach and drugs compatible with connected / smart drug delivery devices. Further, the chapter includes the list of companies engaged in manufacturing connected drug delivery devices, along with detailed analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters and most active players (in terms of the number of integrated connected drug delivery devices manufactured).
  • An extensive analysis of the overall market landscape of add-on sensors, featuring insights based on several relevant parameters, such as stage of development (approved / launched and under development), launch year of device, compatible device (handheld injectors, inhalers and others), route of administration (inhalation, subcutaneous, ophthalmic and oral), therapeutic area (respiratory disorder, metabolic disorder, growth disorder and infectious disease), target indication, key features (audio / visual alerts and reminders / notifications), mode of connectivity (Bluetooth, USB, internet connectivity, near field communication), availability of companion mobile application and availability of data storage / cloud platform. It also includes tabulated information on regulatory approvals, geographical reach and drugs that can be delivered using add-on sensors (in combination with conventional drug delivery devices). Further, the chapter presents a list of companies engaged in manufacturing add-on sensors for drug delivery devices, along with detailed analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters and most active players (in terms of the number of add-on sensors manufactured).
  • An insightful competitiveness analysis of the connected drug delivery devices and add-on sensors, based on the manufacturer strength (in terms of years of establishment and company size) and portfolio strength (in terms of stage of development, route of administration, therapeutic area, key features, mode of connectivity and availability of data storage / cloud platform).
  • A comprehensive set of profiles of leading players manufacturing connected drug delivery devices, based in North America, Europe and Asia-Pacific (shortlisted based on the number of connected drug delivery devices / add-on sensors offered), wherein each profile features a brief overview of the company (including information on their year of establishment, location of headquarters, number of employees, leadership team, business segments and contact details), financial information (if available), connected drug delivery devices portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed and ongoing clinical trials related to connected drug delivery devices, during the time period pre-2011-2020, based on several relevant parameters, such as trial registration year, enrolled patient population, trial phase, trial status, type of device, type of sponsor / collaborator, therapeutic area, study design (type of trial masking, type of intervention model, trial purpose and design allocation), leading industry players (based on number of clinical trials), leading connected / smart drug delivery devices (based on number of clinical trials) and geography.
  • An exhaustive list of the partnerships and collaborations, inked between various stakeholders in the connected drug delivery devices market (during the period 2020-2024), which have been analyzed based on several parameters, such as year of partnership, type of partnership, class of device, type of integrated device, compatible device and most active players (in terms of number of partnerships signed). It also provides analysis of the regional distribution of the companies involved in these agreements.
  • A comprehensive discussion of the funding and investments raised by connected drug delivery device manufacturers, during the period 2020-2024, based on relevant parameters, such as year of funding, amount invested (USD million), type of funding, class of device, geography, most active players (in terms of number of funding instances and amount raised), and most active investors (in terms of number of funding instances).
  • An in-depth value chain analysis featuring a discussion on various steps involved in the development of connected / smart drug delivery devices, including research and development (R&D), product manufacturing and assembly, product distribution, marketing and sales, and post-market surveillance, along with the information on cost requirements across each of the aforementioned stages.
  • Detailed case studies on the two most prevalent diseases (namely, asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.
  • An informative summary of various guidelines established and issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.
  • A thorough discussion on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of connected drug delivery devices market; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A comprehensive assessment of the current market size and opportunity, and future growth potential for the connected drug delivery device manufacturers over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided informed projections on the market's evolution, till 2035. The report also provides light on the likely distribution of the current and forecasted opportunity within the connected drug delivery devices market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
  • Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices industry across type of device, such as connected / smart wearable injectors, connected / smart inhalers, connected / smart pen injectors, connected / smart autoinjectors and connected / smart needle free drug delivery devices.
  • Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices market across mode of connectivity, such as Bluetooth-enabled devices, near field communication-enabled devices, cellular-enabled devices and wide area network-enabled devices.
  • Detailed forecasted estimates of the current and future opportunity within the market for connected drug delivery devices across route of administration, such as parenteral and inhalational.
  • Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices industry across therapeutic area, such as metabolic disorders, respiratory disorders, autoimmune disorders and other disorders.
  • Detailed forecasted estimates of the current and future opportunity within the connected drug delivery devices market across geographical regions, such as North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and Rest of the Europe), Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Israel, Saudi Arabia and Rest of the Middle East and North Africa), and Latin America and Rest of the World (Brazil, Argentina and other countries).

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Connected Drug Delivery Devices Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Companies Profiled

  • Bigfoot Biomedical

BIOCORP

  • Eitan Medical
  • E3D Elcam Drug Delivery Device
  • EoFlow
  • Gerresheimer
  • Insulet
  • Medtronic
  • Medtrum
  • Nemera
  • Phillips-Medisize
  • Roche
  • Sonceboz
  • SOOIL Development
  • Tandem Diabetes Care
  • West Pharmaceutical Services
  • Ypsomed

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Key Market Segmentation
  • 3.7. Robust Quality Control
  • 3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Overview of Major Currencies Affecting the Market
      • 4.2.2.2. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Exchange Impact
      • 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Medication Adherence
    • 6.2.1. Digital Tools for Improving Medication Adherence
  • 6.3. Overview of Connected / Smart Drug Delivery Devices
  • 6.4. Key Design Features and Development Process
  • 6.5. Classification of Connected / Smart Drug Delivery Devices
    • 6.5.1. Type of Device
      • 6.5.1.1. Connected Inhalers
      • 6.5.1.2. Connected Handheld Injectors
      • 6.5.1.3. Smart Pills
      • 6.5.1.4. Smart Implantable Devices
    • 6.5.2. Type of Technology
  • 6.6. Regulatory Guidelines for Connected / Smart Drug Delivery Devices
  • 6.7. Advantages and Limitations of Connected / Smart Drug Delivery Devices
  • 6.8. Impact of COVID-19 on Connected / Smart Drug Delivery Devices Domain
  • 6.9. Future Perspectives

7. MARKET LANDSCAPE: CONNECTED / SMART DRUG DELIVERY DEVICES

  • 7.1. Chapter Overview
  • 7.2. Connected / Smart Drug Delivery Devices: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Launch Year
    • 7.2.3. Analysis by Type of Integrated Device
    • 7.2.4. Analysis by Route of Administration
    • 7.2.5. Analysis by Therapeutic Area
    • 7.2.6. Analysis by Target Indication
    • 7.2.7. Analysis by Key Features
    • 7.2.8. Analysis by Mode of Connectivity
    • 7.2.9. Analysis by Availability of Companion Mobile Application
    • 7.2.10. Analysis by Availability of Data Storage / Cloud Platform
  • 7.3. Connected / Smart Drug Delivery Device Manufacturers: Overall Market Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Year of Establishment and Location of Headquarters
    • 7.3.5. Analysis by Company Size and Location of Headquarters
    • 7.3.6. Most Active Players: Analysis by Number of Connected / Smart Drug Delivery Devices Manufactured

8. MARKET LANDSCAPE: ADD-ON SENSORS

  • 8.1. Chapter Overview
  • 8.2. Add-on Sensors: Overall Market Landscape
    • 8.2.1. Analysis by Stage of Development
    • 8.2.2. Analysis by Launch Year
    • 8.2.3. Analysis by Compatible Device
    • 8.2.4. Analysis by Route of Administration
    • 8.2.5. Analysis by Therapeutic Area
    • 8.2.6. Analysis by Target Indication
    • 8.2.7. Analysis by Key Features
    • 8.2.8. Analysis by Mode of Connectivity
    • 8.2.9. Analysis by Availability of Companion Mobile Application
    • 8.2.10. Analysis by Availability of Data Storage / Cloud Platform
  • 8.3. Add-on Sensor Manufacturers: Overall Market Landscape
    • 8.3.1. Analysis by Year of Establishment
    • 8.3.2. Analysis by Company Size
    • 8.3.3. Analysis by Location of Headquarters
    • 8.3.4. Analysis by Year of Establishment and Location of Headquarters
    • 8.3.5. Analysis by Company Size and Location of Headquarters
    • 8.3.6. Most Active Players: Analysis by Number of Add-on Sensors Manufactured

9. PRODUCT COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. Connected Drug Delivery Devices and Add-on Sensors: Product Competitiveness Analysis
    • 9.4.1. Connected / Smart Drug Delivery Devices
      • 9.4.1.1. Smart Handheld Injectors (Peer Group 1a)
      • 9.4.1.2. Smart Wearable Injectors (Peer Group 1b)
      • 9.4.1.3. Other Integrated Devices (Peer Group 1c)
    • 9.4.2. Add-on Sensors ((Peer Group 2)

10. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN NORTH AMERICA

  • 10.1. Chapter Overview
  • 10.2. Leading Connected / Smart Drug Delivery Device Manufacturers
    • 10.2.1. Medtronic
      • 10.2.1.1. Company Overview
      • 10.2.1.2. Financial Information
      • 10.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
      • 10.2.1.4. Recent Developments and Future Outlook
    • 10.2.2. Insulet
      • 10.2.2.1. Company Overview
      • 10.2.2.2. Financial Information
      • 10.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
      • 10.2.2.4. Recent Developments and Future Outlook
    • 10.2.3. Tandem Diabetes Care
      • 10.2.3.1. Company Overview
      • 10.2.3.2. Financial Information
      • 10.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
      • 10.2.3.4. Recent Developments and Future Outlook
  • 10.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
    • 10.3.1. Bigfoot Biomedical
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
    • 10.3.2. Phillips-Medisize
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Connected / Smart Drug Delivery Devices Portfolio
    • 10.3.3. West Pharmaceutical Services
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Connected / Smart Drug Delivery Devices Portfolio

11. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN EUROPE

  • 11.1. Chapter Overview
  • 11.2. Leading Connected / Smart Drug Delivery Device Manufacturers
    • 11.2.1. BIOCORP
      • 11.2.1.1. Company Overview
      • 11.2.1.2. Financial Information
      • 11.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
      • 11.2.1.4. Recent Developments and Future Outlook
    • 11.2.2. Gerresheimer
      • 11.2.2.1. Company Overview
      • 11.2.2.2. Financial Information
      • 11.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
      • 11.2.2.4. Recent Developments and Future Outlook
    • 11.2.3. Roche
      • 11.2.3.1. Company Overview
      • 11.2.3.2. Financial Information
      • 11.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
      • 11.2.3.4. Recent Developments and Future Outlook
    • 11.2.4. Ypsomed
      • 11.2.4.1. Company Overview
      • 11.2.4.2. Financial Information
      • 11.2.4.3. Connected / Smart Drug Delivery Devices Portfolio
      • 11.2.4.4. Recent Developments and Future Outlook
  • 11.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
    • 11.3.1. Nemera
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
    • 11.3.2. Sonceboz
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

12. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

  • 12.1. Chapter Overview
  • 12.2. Leading Connected / Smart Drug Delivery Device Manufacturers
    • 12.2.1. Medtrum
      • 12.2.1.1. Company Overview
      • 12.2.1.2. Connected / Smart Drug Delivery Devices Portfolio
      • 12.2.1.3. Recent Developments and Future Outlook
    • 12.2.2. SOOIL Development
      • 12.2.2.1. Company Overview
      • 12.2.2.2. Connected / Smart Drug Delivery Devices Portfolio
      • 12.2.2.3. Recent Developments and Future Outlook
    • 12.2.3. EOFlow
      • 12.2.3.1. Company Overview
      • 12.2.3.2. Financial Information
      • 12.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
      • 12.2.3.4. Recent Developments and Future Outlook
  • 12.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
    • 12.3.1. Eitan Medical
      • 12.3.1.1. Company Overview
      • 12.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
    • 12.3.2. E3D Elcam Drug Delivery Device
      • 12.3.2.1. Company Overview
      • 12.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

13. CLINICAL TRIAL ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Connected / Smart Drug Delivery Devices and Add-on Sensors: Clinical Trial Analysis
    • 13.3.1. Analysis by Trial Registration Year
    • 13.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
    • 13.3.3. Analysis by Trial Phase
    • 13.3.4. Analysis by Trial Status
    • 13.3.5. Analysis by Type of Device
    • 13.3.6. Analysis by Type of Sponsor / Collaborator
    • 13.3.7. Analysis by Therapeutic Area
    • 13.3.8. Analysis by Study Design
    • 13.3.9. Leading Industry Players: Analysis by Number of Registered Trials
    • 13.3.10. Leading Connected / Smart Drug Delivery Devices and Add-on Sensors: Analysis by Number of Registered Trials
    • 13.3.11. Analysis by Geography
      • 13.3.11.1. Analysis of Number of Registered Trials by Trial Status and Geography
      • 13.3.11.2. Analysis of Enrolled Patient Population by Trial Status and Geography

14. PARTNERSHIPS AND COLLABORATIONS

  • 14.1. Chapter Overview
  • 14.2. Partnership Models
  • 14.3. Connected / Smart Drug Delivery Devices: Partnerships and Collaborations
    • 14.3.1. Analysis by Year of Partnership
    • 14.3.2. Analysis by Type of Partnership
    • 14.3.3. Analysis by Year and Type of Partnership
    • 14.3.4. Analysis by Class of Device
    • 14.3.5. Analysis by Type of Integrated Device
    • 14.3.6. Analysis by Compatible Device
    • 14.3.7. Most Active Players: Analysis by Number of Partnerships
    • 14.3.8. Analysis by Geography
      • 14.3.8.1. Intracontinental and Intercontinental Deals
      • 14.3.8.2. Local and International Deals

15. FUNDING AND INVESTMENTS

  • 15.1. Chapter Overview
  • 15.2. Funding Models
  • 15.3. Connected / Smart Drug Delivery Devices: Funding and Investments, 2015-2020
    • 15.3.1. Analysis by Year of Funding
    • 15.3.2. Analysis by Amount Invested
    • 15.3.3. Analysis by Type of Funding
      • 15.3.3.1. Analysis of Funding Instances
      • 15.3.3.2. Analysis of Amount Invested
    • 15.3.4. Analysis of Funding Instances by Year and Type of Funding
    • 15.3.5. Analysis by Class of Device
    • 15.3.6. Analysis by Geography
    • 15.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 15.3.8. Most Active Players: Analysis by Amount Raised
    • 15.3.9. Leading Investors: Analysis by Number of Funding Instances
  • 15.4. Summary of Funding and Investments, Till 2020
  • 15.5. Connected / Smart Drug Delivery Devices: Funding and Investments, 2021-2024

16. VALUE CHAIN / COST PRICE ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Connected / Smart Drug Delivery Devices: Value Chain
  • 16.3. Cost Distribution Across the Value Chain
    • 16.3.1. Concept Development and Proof of Concept
    • 16.3.2. Research and Product Development
    • 16.3.3. Conduct of Clinical Trials
    • 16.3.4. Regulatory Approvals
    • 16.3.5. Manufacturing and Product Assembly
    • 16.3.6. Application Development
    • 16.3.7. Marketing and Sales

17. REGULATORY LANDSCAPE FOR CONNECTED / SMART DRUG DELIVERY DEVICES

  • 17.1. Chapter Overview
  • 17.2. Regulatory Approval of Combination Products in North America
    • 17.2.1. Regulatory Approval of Combination Products in the US
      • 17.2.1.1. Overview
      • 17.2.1.2. Historical Background
      • 17.2.1.3. Role of Regulatory Bodies in Product Approval
    • 17.2.2. Regulatory Approval of Combination Products in Canada
      • 17.2.2.1. Overview
      • 17.2.2.2. Role of Regulatory Bodies in Product Approval
    • 17.2.3. Regulatory Approval of Combination Products in Mexico
      • 17.2.3.1. Overview
      • 17.2.3.2. Role of Regulatory Bodies in Product Approval
  • 17.3. Regulatory Approval of Combination Products in Europe
    • 17.3.1. Regulatory Approval of Combination Products in EU5 Countries
      • 17.3.1.1. Overview
      • 17.3.1.2. Role of Regulatory Bodies in Product Approval
  • 17.4. Regulatory Approval of Combination Products in Asia-Pacific
    • 17.4.1. Regulatory Approval of Combination Products in Japan
      • 17.4.1.1. Overview
      • 17.4.1.2. Role of Regulatory Bodies in Product Approval
    • 17.4.2. Regulatory Approval of Combination Products in China
      • 17.4.2.1. Overview
      • 17.4.2.2. Role of Regulatory Bodies in Product Approval
    • 17.4.3. Regulatory Approval of Combination Products in India
      • 17.4.3.1. Overview
      • 17.4.3.2. Role of Regulatory Bodies in Product Approval
    • 17.4.4. Regulatory Approval of Combination Products in South Korea
      • 17.4.4.1. Overview
      • 17.4.4.2. Role of Regulatory Bodies in Product Approval
    • 17.4.5. Regulatory Approval of Combination Products in Australia
      • 17.4.5.1. Overview
      • 17.4.5.2. Role of Regulatory Bodies in Product Approval
  • 17.5. Regulatory Approval of Combination Products in Middle East and North Africa
    • 17.5.1. Regulatory Approval of Combination Products in Saudi Arabia
      • 17.5.1.1. Overview
      • 17.5.1.2. Role of Regulatory Bodies in Product Approval
    • 17.5.2. Regulatory Approval of Combination Products in United Arab Emirates
      • 17.5.2.1. Overview
      • 17.5.2.2. Role of Regulatory Bodies in Product Approval
  • 17.6. Regulatory Approval of Combination Products in Latin America
    • 17.6.1. Regulatory Approval of Combination Products in Brazil
      • 17.6.1.1. Overview
      • 17.6.1.2. Role of Regulatory Bodies in Product Approval
    • 17.6.2. Regulatory Approval of Combination Products in Argentina
      • 17.6.2.1. Overview
      • 17.6.2.2. Role of Regulatory Bodies in Product Approval
  • 17.7. Connected Devices: Other Measures for Testing Safety, Effectiveness and Performance
  • 17.8. Ensuring Security of Data Captured
  • 17.9. Concluding Remarks

18. CASE STUDIES: APPLICATION OF CONNECTED DRUG DELIVERY DEVICES TO IMPROVE MEDICATION ADHERENCE

  • 18.1. Chapter Overview
  • 18.2. Case Study I: Diabetes
    • 18.2.1. Disease Overview
    • 18.2.2. Key Statistics
    • 18.2.3. Economic Burden due to Non-Adherence
    • 18.2.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence
  • 18.3. Case Study II: Asthma
    • 18.3.1. Disease Overview
    • 18.3.2. Key Statistics
    • 18.3.3. Economic Burden due to Non-Adherence
    • 18.3.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence

19. SWOT ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Strengths
    • 19.2.1. Ability to Minimize / Eliminate Medication Errors
    • 19.2.2. Economic Advantages
    • 19.2.3. Technological Advancements
  • 19.3. Weaknesses
    • 19.3.1. Cybersecurity
    • 19.3.2. Stringent Regulatory Approvals
    • 19.3.3. High Developmental Costs
  • 19.4. Opportunities
    • 19.4.1. Growing Prevalence of Chronic Disorders
    • 19.4.2. Increasing Adoption of Digital Health Technologies
    • 19.4.3. Rising Partnership and Investment Activity
  • 19.5. Threats
    • 19.5.1. Material Compatibility Issues
    • 19.5.2. Availability of Alternative Drug Delivery Devices
    • 19.5.3. Concern Related to Product Recalls in Past
  • 19.6. Comparison of SWOT Factors

20. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET

  • 20.1. Chapter Overview
  • 20.2. Assumptions and Methodology
  • 20.3. Global Connected Drug Delivery Devices Market, till 2035
    • 20.3.1. Scenario Analysis
      • 20.3.1.1. Conservative Scenario
      • 20.3.1.2. Optimistic Scenario
  • 20.4. Key Market Segmentations
  • 20.5. Leading Industry Players

21. CONNECTED DRUG DELIVERY DEVICES MARKET, BY TYPE OF DEVICE

  • 21.1. Chapter Overview
  • 21.2. Assumptions and Methodology
  • 21.3. Connected Drug Delivery Devices Market: Distribution by Type of Device, 2020, 2024 and 2035
    • 21.3.1. Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, till 2035
    • 21.3.2. Connected Drug Delivery Devices Market for Connected / Smart Inhalers, till 2035
    • 21.3.3. Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, till 2035
    • 21.3.4. Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, till 2035
    • 21.3.5. Connected Drug Delivery Devices Market for Connected / Smart Needle-free Injection Systems, till 2035
  • 21.4. Data Triangulation and Validation

22. CONNECTED DRUG DELIVERY DEVICES MARKET, BY MODE OF CONNECTIVITY

  • 22.1. Chapter Overview
  • 22.2. Assumptions and Methodology
  • 22.3. Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity, 2020, 2024 and 2035
    • 22.3.1. Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, till 2035
    • 22.3.2. Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, till 2035
    • 22.3.3. Connected Drug Delivery Devices Market for Cellular-enabled Devices, till 2035
    • 22.3.4. Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, till 2035
  • 22.4. Data Triangulation and Validation

23. CONNECTED DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION

  • 23.1. Chapter Overview
  • 23.2. Assumptions and Methodology
  • 23.3. Connected Drug Delivery Devices Market: Distribution by Route of Administration, 2020, 2024 and 2035
    • 23.3.1. Connected Drug Delivery Devices Market for Parenteral Administration, till 2035
    • 23.3.2. Connected Drug Delivery Devices Market for Inhalational Administration, till 2035
  • 23.4. Data Triangulation and Validation

24. CONNECTED DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC AREA

  • 24.1. Chapter Overview
  • 24.2. Assumptions and Methodology
  • 24.3. Connected Drug Delivery Devices Market: Distribution by Therapeutic Area, 2020, 2024 and 2035
    • 24.3.1. Connected Drug Delivery Devices Market for Metabolic Disorders, till 2035
    • 24.3.2. Connected Drug Delivery Devices Market for Respiratory Disorders, till 2035
    • 24.3.3. Connected Drug Delivery Devices Market for Autoimmune Disorders, till 2035
    • 24.3.4. Connected Drug Delivery Devices Market for Other Disorders, till 2035
  • 24.4. Data Triangulation and Validation

25. CONNECTED DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Assumptions and Methodology
  • 25.3. Connected Drug Delivery Devices Market: Distribution by Geographical Regions, 2020, 2024 and 2035
    • 25.3.1. Connected Drug Delivery Devices Market in North America, till 2035
      • 25.3.1.1. Connected Drug Delivery Devices Market in the US, till 2035
      • 25.3.1.2. Connected Drug Delivery Devices Market in Canada, till 2035
    • 25.3.2. Connected Drug Delivery Devices Market in Europe, till 2035
      • 25.3.2.1. Connected Drug Delivery Devices Market in the UK, till 2035
      • 25.3.2.2. Connected Drug Delivery Devices Market in Germany, till 2035
      • 25.3.2.3. Connected Drug Delivery Devices Market in France, till 2035
      • 25.3.2.4. Connected Drug Delivery Devices Market in Italy, till 2035
      • 25.3.2.5. Connected Drug Delivery Devices Market in Spain, till 2035
      • 25.3.2.6. Connected Drug Delivery Devices Market in Rest of the Europe, till 2035
    • 25.3.3. Connected Drug Delivery Devices Market in Asia-Pacific, till 2035
      • 25.3.3.1. Connected Drug Delivery Devices Market in China, till 2035
      • 25.3.3.2. Connected Drug Delivery Devices Market in India, till 2035
      • 25.3.3.3. Connected Drug Delivery Devices Market in Japan, till 2035
      • 25.3.3.4. Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, till 2035
    • 25.3.4. Connected Drug Delivery Devices Market in Middle East and North Africa, till 2035
      • 25.3.4.1. Connected Drug Delivery Devices Market in Egypt, till 2035
      • 25.3.4.2. Connected Drug Delivery Devices Market in Israel, till 2035
      • 25.3.4.3. Connected Drug Delivery Devices Market in Saudi Arabia, till 2035
      • 25.3.4.4. Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, till 2035
    • 25.3.5. Connected Drug Delivery Devices Market in Latin America and Rest of the World, till 2035
      • 25.3.5.1. Connected Drug Delivery Devices Market in Brazil, till 2035
      • 25.3.5.2. Connected Drug Delivery Devices Market in Argentina, till 2035
      • 25.3.5.3. Connected Drug Delivery Devices Market in Other Countries, till 2035
  • 25.4. Data Triangulation and Validation

26. CONCLUDING REMARKS

27. EXECUTIVE INSIGHTS

  • 27.1. Chapter Overview
  • 27.2. Phillips-Medisize
    • 27.2.1. Company Snapshot
    • 27.2.2. Interview Transcript: Candace Bowering, Senior Director, Global Strategic Marketing, Medical
  • 27.3. Cognita Labs
    • 27.3.1. Company Snapshot
    • 27.3.2. Interview Transcript: Gaurav Patel, Co-founder and Chief Executive Officer
  • 27.4. Portal Instruments
    • 27.4.1. Company Snapshot
    • 27.4.2. Interview Transcript: Patrick Anquetil, Founder and Chief Executive Officer
  • 27.5. Enable Injections
    • 27.5.1. Company Snapshot
    • 27.5.2. Interview Transcript: Michael D. Hooven, Chief Executive Officer and President
  • 27.6. Amiko
    • 27.6.1. Company Snapshot
    • 27.6.2. Interview Transcript: Duilio Macchi, Chief Executive Officer
  • 27.7. Elcam Medical
    • 27.7.1. Company Snapshot
    • 27.7.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
  • 27.8. West Pharmaceutical Services
    • 27.8.1. Company Snapshot
    • 27.8.2. Interview Transcript: Tiffany Burke, Director (Global Communications) and Graham Reynolds, Former Vice President (Strategic Partnerships and Business Development)
  • 27.9. Avoset Health (acquired by Eitan Medical)
    • 27.9.1. Company Snapshot
    • 27.9.2. Interview Transcript: Shaul Eitan, Former Chief Executive Officer
  • 27.10. Phillips-Medisize
    • 27.10.1. Company Snapshot
    • 27.10.2. Interview Transcript: Neil Williams, Former Director (Front-end Innovation and Head of Connected Health)
  • 27.11. Sorrel Medical (acquired by LTS lohmann therapie-systeme)
    • 27.11.1. Company Snapshot
    • 27.11.2. Interview Transcript: Mindy Katz, Former Vice President (Marketing and Alliance Management)
  • 27.12. etectRx
    • 27.12.1. Company Snapshot
    • 27.12.2. Interview Transcript: Anonymous, Advisor (Strategy and Business Development)

28. APPENDIX 1: TABULATED DATA

29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

30. APPENDIX 3: PARTNERSHIPS AND COLLABORATIONS, 2015-2020

List of Tables

  • Table 7.1 Connected / Smart Drug Delivery Devices: Information on Manufacturer, Stage of Development, Launch Year, Type of Integrated Device and Route of Administration
  • Table 7.2 Connected / Smart Drug Delivery Devices: Information on Therapeutic Area, Target Indication and Key Features
  • Table 7.3 Connected / Smart Drug Delivery Devices: Information on Mode of Connectivity, Availability of Companion Mobile Application, Compatible Operating System and Availability of Data Storage / Cloud Platform
  • Table 7.4 Connected / Smart Drug Delivery Devices: Information on Regulatory Approvals, Geographical Reach and Compatible Drug
  • Table 7.5 Connected / Smart Drug Delivery Device Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 8.1 Add-on Sensors: Information on Manufacturer, Stage of Development, Launch Year, Type of Device and Route of Administration
  • Table 8.2 Add-on Sensors: Information on Therapeutic Area, Target Indication and Key Features
  • Table 8.3 Add-on Sensors: Information on Connectivity Solution, Availability of Companion Mobile Application, Compatible Operating System and Availability of Data Storage / Cloud Platform
  • Table 8.4 Add-on Sensors: Information on Regulatory Approvals, Geographical Reach and Drug Delivered
  • Table 8.5 Add-on Sensor Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 9.1 Product Competitiveness Analysis: Connected / Smart Drug Delivery Devices
  • Table 10.1 Connected / Smart Drug Delivery Device Manufacturers in North America: List of Companies Profiled
  • Table 10.2 Medtronic: Company Overview
  • Table 10.3 Medtronic: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.4 Medtronic: Recent Developments and Future Outlook
  • Table 10.5 Insulet: Company Overview
  • Table 10.6 Insulet: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.7 Insulet: Recent Developments and Future Outlook
  • Table 10.8 Tandem Diabetes Care: Company Overview
  • Table 10.9 Tandem Diabetes Care: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.10 Tandem Diabetes Care: Recent Developments and Future Outlook
  • Table 10.11 Bigfoot Biomedical: Company Overview
  • Table 10.12 Bigfoot Biomedical: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.13 Phillips-Medsize: Company Overview Table 10.3 BIOCORP: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.14 Phillips-Medsize: Connected / Smart Drug Delivery Devices Portfolio
  • Table 10.15 West Pharmaceutical Services: Company Overview
  • Table 10.16 West Pharmaceutical Services: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.1 Connected / Smart Drug Delivery Device Manufacturers in Europe: List of Companies Profiled
  • Table 11.2 BIOCORP: Company Overview
  • Table 11.3 BIOCORP: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.4 BIOCORP: Recent Developments and Future Outlook
  • Table 11.5 Gerresheimer: Company Overview
  • Table 11.6 Gerresheimer: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.7 Gerresheimer: Recent Developments and Future Outlook
  • Table 11.8 Roche: Company Overview
  • Table 11.9 Roche: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.10 Roche: Recent Developments and Future Outlook
  • Table 11.11 Ypsomed: Company Overview
  • Table 11.12 Ypsomed: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.13 Ypsomed: Recent Developments and Future Outlook
  • Table 11.14 Nemera: Company Overview
  • Table 11.15 Nemera: Connected / Smart Drug Delivery Devices Portfolio
  • Table 11.16 Sonceboz: Company Overview
  • Table 11.17 Sonceboz: Connected / Smart Drug Delivery Devices Portfolio
  • Table 12.1 Connected / Smart Drug Delivery Device Manufacturers in Asia-Pacific and Rest of the World: List of Companies Profiled
  • Table 12.2 Medtrum: Company Overview
  • Table 12.3 Medtrum: Connected / Smart Drug Delivery Devices Portfolio
  • Table 12.4 SOOIL Development: Company Overview
  • Table 12.5 SOOIL Development: Connected / Smart Drug Delivery Devices Portfolio
  • Table 12.6 SOOIL Development: Recent Developments and Future Outlook
  • Table 12.7 EOFlow: Company Overview
  • Table 12.8 EOFlow: Connected / Smart Drug Delivery Devices Portfolio
  • Table 12.9 EOFlow: Recent Developments and Future Outlook
  • Table 12.10 Eitan Medical: Company Overview
  • Table 12.11 Eitan Medical: Connected / Smart Drug Delivery Devices Portfolio
  • Table 12.12 E3D Elcam Drug Delivery Device: Company Overview
  • Table 12.13 E3D Elcam Drug Delivery Device: Connected / Smart Drug Delivery Devices Portfolio
  • Table 14.1 Connected / Smart Drug Delivery Devices: List of Partnerships and Collaborations, 2021-2024
  • Table 14.2 Partnerships and Collaborations: Information on Type of Agreement (Country and Region)
  • Table 15.1 Connected / Smart Drug Delivery Devices: List of Funding and Investments, 2015-2020
  • Table 15.2 Connected / Smart Drug Delivery Devices: Information on Type of Device and Type of Integrated Device
  • Table 15.3 Connected / Smart Drug Delivery Devices: List of Funding and Investments, 2021-2024
  • Table 17.1 FDA Centers for Drug and Device Approval
  • Table 17.2 Regulatory Review Timelines for Combination Products in the US
  • Table 17.3 Regulatory Bodies in EU5 Countries
  • Table 17.4 SFDA: Regulatory Review Timeline
  • Table 20.1 Connected Drug Delivery Devices Market: Leading Industry Players
  • Table 27.1 Phillips-Medisize: Company Overview

Table 27.2: Cognita Labs: Company Overview

  • Table 27.3 Portal Instruments: Company Overview
  • Table 27.4 Enable Injections: Company Overview
  • Table 27.5 Amiko: Company Overview
  • Table 27.6 Elcam Medical: Company Overview
  • Table 27.7 West Pharmaceutical Services: Company Overview
  • Table 27.8 Avoset Health: Company Overview
  • Table 27.9 Phillips-Medisize: Company Overview
  • Table 27.10 Sorrel Medical: Company Overview
  • Table 27.11 etectRx: Company Overview
  • Table 28.1 Connected / Smart Drug Delivery Devices: Distribution by Stage of Development
  • Table 28.2 Connected / Smart Drug Delivery Devices: Distribution by Launch Year
  • Table 28.3 Connected / Smart Drug Delivery Devices: Distribution by Type of Integrated Device
  • Table 28.4 Connected / Smart Drug Delivery Devices: Distribution by Route of Administration
  • Table 28.5 Connected / Smart Drug Delivery Devices: Distribution by Therapeutic Area
  • Table 28.6 Connected / Smart Drug Delivery Devices: Distribution by Target Indication
  • Table 28.7 Connected / Smart Drug Delivery Devices: Distribution by Key Features
  • Table 28.8 Connected / Smart Drug Delivery Devices: Distribution by Mode of Connectivity
  • Table 28.9 Connected / Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
  • Table 28.10 Connected / Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
  • Table 28.11 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment
  • Table 28.12 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size
  • Table 28.13 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Location of Headquarters
  • Table 28.14 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Table 28.15 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
  • Table 28.16 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Devices Manufactured
  • Table 28.17 Add-on Sensors: Distribution by Stage of Development
  • Table 28.18 Add-on Sensors: Distribution by Launch Year
  • Table 28.19 Add-on Sensors: Distribution by Compatible Device
  • Table 28.20 Add-on Sensors: Distribution by Route of Administration
  • Table 28.21 Add-on Sensors: Distribution by Therapeutic Area
  • Table 28.22 Add-on Sensors: Distribution by Target Indication
  • Table 28.23 Add-on Sensors: Distribution by Key Features
  • Table 28.24 Add-on Sensors: Distribution by Mode of Connectivity
  • Table 28.25 Add-on Sensors: Distribution by Availability of Companion Mobile Application
  • Table 28.26 Add-on Sensors: Distribution by Availability of Data Storage / Cloud Platform
  • Table 28.27 Add-on Sensor Manufacturers: Distribution by Year of Establishment
  • Table 28.28 Add-on Sensor Manufacturers: Distribution by Company Size
  • Table 28.29 Add-on Sensor Manufacturers: Distribution by Location of Headquarters
  • Table 28.30 Add-on Sensor Manufacturers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Table 28.31 Add-on Sensor Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
  • Table 28.32 Most Active Players: Distribution by Number of Add-on Sensors Manufactured
  • Table 28.33 Medtronic: Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Table 28.34 Insulet: Business Segment-wise Revenues and Consolidated Financial Details (USD Million)
  • Table 28.35 Tandem Diabetes Care: Consolidated Financial Details (USD Million)
  • Table 28.36 Gerresheimer: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)
  • Table 28.37 Roche: Business Segment-wise Revenues and Consolidated Financial Details (CHF Billion)
  • Table 28.38 Ypsomed: Business Segment-wise Revenues and Consolidated Financial Details (CHF Million)
  • Table 28.39 Clinical Trial Analysis: Distribution by Trial Registration Year, till 2020
  • Table 28.40 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, till 2020
  • Table 28.41 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 28.42 Clinical Trial Analysis: Distribution by Trial Status
  • Table 28.43 Clinical Trial Analysis: Distribution by Type of Device
  • Table 28.44 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 28.45 Clinical Trial Analysis: Distribution of Number of Registered Trials by Therapeutic Area
  • Table 28.46 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
  • Table 28.47 Clinical Trial Analysis: Distribution by Study Design
  • Table 28.48 Leading Industry Players: Distribution by Number of Registered Trials
  • Table 28.49 Leading Connected / Smart Drug Delivery Devices and Add-on Sensors: Distribution by Number of Registered Trials
  • Table 28.50 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
  • Table 28.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 28.52 Partnerships and Collaborations: Cumulative Year-wise Trend, till 2024
  • Table 28.53 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 28.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership, till 2024
  • Table 28.55 Partnerships and Collaborations: Distribution by Class of Device
  • Table 28.56 Partnerships and Collaborations: Distribution by Type of Integrated Device
  • Table 28.57 Partnerships and Collaborations: Distribution by Compatible Device
  • Table 28.58 Most Active Players: Distribution by Number of Partnerships
  • Table 28.59 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 28.60 Partnerships and Collaborations: Local and International Deals
  • Table 28.61 Funding and Investment Analysis: Cumulative Year-wise Trend, till 2020
  • Table 28.62 Funding and Investment Analysis: Distribution by Amount Invested, till 2020 (USD Million)
  • Table 28.63 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Table 28.64 Funding and Investments: Distribution by Amount Invested by Type of Funding (USD Million)
  • Table 28.65 Distribution of Funding Instances by Year and Type of Funding, 2015-2020
  • Table 28.66 Funding and Investments: Distribution of Funding Instances by Class of Device
  • Table 28.67 Funding and Investments: Distribution of Funding Instances by Geography
  • Table 28.68 Funding and Investments: Distribution of Funding Instances by Geography and Amount Invested (USD Million)
  • Table 28.69 Most Active Players: Distribution by Number of Funding Instances
  • Table 28.70 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 28.71 Leading Investors: Distribution by Number of Funding Instances
  • Table 28.72 Funding and Investments Summary, till 2020 (USD Million)
  • Table 28.73 Global Connected Drug Delivery Devices Demand, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.74 Global Connected Drug Delivery Devices Demand, till 2035 (Million Units Sold)
  • Table 28.75 Global Connected Drug Delivery Devices Market, Historical Trends, Since 2020 (USD Million)
  • Table 28.76 Global Connected Drug Delivery Devices Market, till 2035 (USD Million)
  • Table 28.77 Connected Drug Delivery Devices Market: Distribution by Type of Device, 2020, 2024 and 2035 (USD Million)
  • Table 28.78 Connected Drug Delivery Devices Demand for Connected / Smart Wearable Injectors, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.79 Connected Drug Delivery Devices Demand for Connected / Smart Wearable Injectors, till 2035 (Million Units Sold)
  • Table 28.80 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, Historical Trends, Since 2020 (USD Million)
  • Table 28.81 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, till 2035 (USD Million)
  • Table 28.82 Connected Drug Delivery Devices Demand for Connected / Smart Inhalers, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.83 Connected Drug Delivery Devices Demand for Connected / Smart Inhalers, till 2035 (Million Units Sold)
  • Table 28.84 Connected Drug Delivery Devices Market for Connected / Smart Inhalers, Historical Trends, since 2020 (USD Million)
  • Table 28.85 Connected Drug Delivery Devices Market for Connected / Smart Inhalers, till 2035 (USD Million)
  • Table 28.86 Connected Drug Delivery Devices Demand for Connected / Smart Pen Injectors, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.87 Connected Drug Delivery Devices Demand for Connected / Smart Pen Injectors, till 2035 (Million Units Sold)
  • Table 28.88 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, Historical Trends, since 2020 (USD Million)
  • Table 28.89 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, till 2035 (USD Million)
  • Table 28.90 Connected Drug Delivery Devices Demand for Connected / Smart Autoinjectors, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.91 Connected Drug Delivery Devices Demand for Connected / Smart Autoinjectors, till 2035 (Million Units Sold)
  • Table 28.92 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, Historical Trends, since 2020 (USD Million)
  • Table 28.93 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, till 2035 (USD Million)
  • Table 28.94 Connected Drug Delivery Devices Demand for Connected / Smart Needle-free Injection Systems, till 2035 (Million Units Sold)
  • Table 28.95 Connected Drug Delivery Devices Demand for Connected / Smart Needle-free Injection Systems, till 2035 (USD Million)
  • Table 28.96 Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity, 2020, 2024 and 2035 (USD Million)
  • Table 28.97 Connected Drug Delivery Devices Demand for Bluetooth-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.98 Connected Drug Delivery Devices Demand for Bluetooth-enabled Devices, till 2035 (Million Units Sold)
  • Table 28.99 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, Historical Trends, since 2020 (USD Million)
  • Table 28.100 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, till 2035 (USD Million)
  • Table 28.101 Connected Drug Delivery Devices Demand for Near-field Communication-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.102 Connected Drug Delivery Devices Demand for Near-field Communication-enabled Devices, till 2035 (Million Units Sold)
  • Table 28.103 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, Historical Trends, since 2020 (USD Million)
  • Table 28.104 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, till 2035 (USD Million)
  • Table 28.105 Connected Drug Delivery Devices Demand for Cellular-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.106 Connected Drug Delivery Devices Demand for Cellular-enabled Devices, till 2035 (Million Units Sold)
  • Table 28.107 Connected Drug Delivery Devices Market for Cellular-enabled Devices, Historical Trends, since 2020 (USD Million)
  • Table 28.108 Connected Drug Delivery Devices Market for Cellular-enabled Devices, till 2035 (USD Million)
  • Table 28.109 Connected Drug Delivery Devices Demand for Wide Area Network-enabled Devices, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.110 Connected Drug Delivery Devices Demand for Wide Area Network-enabled Devices, till 2035 (Million Units Sold)
  • Table 28.111 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, Historical Trends, since 2020 (USD Million)
  • Table 28.112 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, till 2035 (USD Million)
  • Table 28.113 Connected Drug Delivery Devices Market: Distribution by Route of Administration, 2020, 2024 and 2035 (USD Million)
  • Table 28.114 Connected Drug Delivery Demand for Parenteral Administration, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.115 Connected Drug Delivery Devices Demand for Parenteral Administration, till 2035 (Million Units Sold)
  • Table 28.116 Connected Drug Delivery Devices Market for Parenteral Administration, Historical Trends, since 2020 (USD Million)
  • Table 28.117 Connected Drug Delivery Devices Market for Parenteral Administration, till 2035 (USD Million)
  • Table 28.118 Connected Drug Delivery Devices Demand for Inhalational Administration, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.119 Connected Drug Delivery Devices Demand for Inhalational Administration, till 2035 (Million Units Sold)
  • Table 28.120 Connected Drug Delivery Devices Market for Inhalational Administration, Since 2020 (USD Million)
  • Table 28.121 Connected Drug Delivery Devices Market for Inhalational Administration, till 2035 (USD Million)
  • Table 28.122 Connected Drug Delivery Devices Market: Distribution by Therapeutic Area, 2020, 2024 and 2035 (USD Million)
  • Table 28.123 Connected Drug Delivery Devices Demand for Metabolic Disorders, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.124 Connected Drug Delivery Devices Demand for Metabolic Disorders, till 2035 (Million Units Sold)
  • Table 28.125 Connected Drug Delivery Devices Market for Metabolic Disorders, Historical Trends, since 2020 (USD Million)
  • Table 28.126 Connected Drug Delivery Devices Market for Metabolic Disorders, till 2035 (USD Million)
  • Table 28.127 Connected Drug Delivery Devices Demand for Respiratory Disorders, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.128 Connected Drug Delivery Devices Demand for Respiratory Disorders, till 2035 (Million Units Sold)
  • Table 28.129 Connected Drug Delivery Devices Market for Respiratory Disorders, Historical Trends, since 2020 (USD Million)
  • Table 28.130 Connected Drug Delivery Devices Market for Respiratory Disorders, till 2035 (USD Million)
  • Table 28.131 Connected Drug Delivery Devices Demand for Autoimmune Disorders, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.132 Connected Drug Delivery Devices Demand for Autoimmune Disorders, till 2035 (Million Units Sold)
  • Table 28.133 Connected Drug Delivery Devices Market for Autoimmune Disorders, Historical Trends, since 2020 (USD Million)
  • Table 28.134 Connected Drug Delivery Devices Market for Autoimmune Disorders, till 2035 (USD Million)
  • Table 28.135 Connected Drug Delivery Devices Demand for Other Disorders, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.136 Connected Drug Delivery Devices Demand for Other Disorders, till 2035 (Million Units Sold)
  • Table 28.137 Connected Drug Delivery Devices Market for Other Disorders, Historical Trends, since 2020 (USD Million)
  • Table 28.138 Connected Drug Delivery Devices Market for Other Disorders, till 2035 (USD Million)
  • Table 28.139 Connected Drug Delivery Devices Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
  • Table 28.140 Connected Drug Delivery Devices Demand in North America, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.141 Connected Drug Delivery Devices Demand in North America, till 2035 (Million Units Sold)
  • Table 28.142 Connected Drug Delivery Devices Market in North America, Historical Trends, since 2020 (USD Million)
  • Table 28.143 Connected Drug Delivery Devices Market in North America, till 2035 (USD Million)
  • Table 28.144 Connected Drug Delivery Devices Market in the US, Historical Trends, Since 2020 (USD Million)
  • Table 28.145 Connected Drug Delivery Devices Market in the US, till 2035 (USD Million)
  • Table 28.146 Connected Drug Delivery Devices Market in Canada, Historical Trends, since 2020 (USD Million)
  • Table 28.147 Connected Drug Delivery Devices Market in Canada, till 2035 (USD Million)
  • Table 28.148 Connected Drug Delivery Devices Demand in Europe, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.149 Connected Drug Delivery Devices Demand in Europe, till 2035 (Million Units Sold)
  • Table 28.150 Connected Drug Delivery Devices Market in Europe, Historical Trends, since 2020 (USD Million)
  • Table 28.151 Connected Drug Delivery Devices Market in Europe, till 2035 (USD Million)
  • Table 28.152 Connected Drug Delivery Devices Market in the UK, Historical Trends, since 2020 (USD Million)
  • Table 28.153 Connected Drug Delivery Devices Market in the UK, till 2035 (USD Million)
  • Table 28.154 Connected Drug Delivery Devices Market in Germany, Historical Trends, since 2020 (USD Million)
  • Table 28.155 Connected Drug Delivery Devices Market in Germany, till 2035 (USD Million)
  • Table 28.156 Connected Drug Delivery Devices Market in France, Historical Trends, Since 2020 (USD Million)
  • Table 28.157 Connected Drug Delivery Devices Market in France, till 2035 (USD Million)
  • Table 28.158 Connected Drug Delivery Devices Market in Italy, Historical Trends, since 2020 (USD Million)
  • Table 28.159 Connected Drug Delivery Devices Market in Italy, till 2035 (USD Million)
  • Table 28.160 Connected Drug Delivery Devices Market in Spain, Historical Trends, since 2020 (USD Million)
  • Table 28.161 Connected Drug Delivery Devices Market in Spain, till 2035 (USD Million)
  • Table 28.162 Connected Drug Delivery Devices Market in Rest of Europe, Historical Trends, since 2020 (USD Million)
  • Table 28.163 Connected Drug Delivery Devices Market in Rest of Europe, till 2035 (USD Million)
  • Table 28.164 Connected Drug Delivery Devices Demand in Asia-Pacific, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.165 Connected Drug Delivery Devices Demand in Asia-Pacific, till 2035 (Million Units Sold)
  • Table 28.166 Connected Drug Delivery Devices Market in Asia-Pacific, Historical Trends, since 2020 (USD Million)
  • Table 28.167 Connected Drug Delivery Devices Market in Asia-Pacific, till 2035 (USD Million)
  • Table 28.168 Connected Drug Delivery Devices Market in China, Historical Trends, since 2020 (USD Million)
  • Table 28.169 Connected Drug Delivery Devices Market in China, till 2035 (USD Million)
  • Table 28.170 Connected Drug Delivery Devices Market in India, Historical Trends, Since 2020 (USD Million)
  • Table 28.171 Connected Drug Delivery Devices Market in India, till 2035 (USD Million)
  • Table 28.172 Connected Drug Delivery Devices Market in Japan, Historical Trends, Since 2020 (USD Million)
  • Table 28.173 Connected Drug Delivery Devices Market in Japan, till 2035 (USD Million)
  • Table 28.174 Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, Historical Trends, since 2020 (USD Million)
  • Table 28.175 Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, till 2035 (USD Million)
  • Table 28.176 Connected Drug Delivery Devices Demand in Middle East and North Africa, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.177 Connected Drug Delivery Devices Demand in Middle East and North Africa, till 2035 (Million Units Sold)
  • Table 28.178 Connected Drug Delivery Devices Market in Middle East and North Africa, Historical Trends, Since 2020 (USD Million)
  • Table 28.179 Connected Drug Delivery Devices Market in Middle East and North Africa, till 2035 (USD Million)
  • Table 28.180 Connected Drug Delivery Devices Market in Egypt, Historical Trends, since 2020 (USD Million)
  • Table 28.181 Connected Drug Delivery Devices Market in Egypt, till 2035 (USD Million)
  • Table 28.182 Connected Drug Delivery Devices Market in Israel, Historical Trends, since 2020 (USD Million)
  • Table 28.183 Connected Drug Delivery Devices Market in Israel, till 2035 (USD Million)
  • Table 28.184 Connected Drug Delivery Devices Market in Saudi Arabia, Historical Trends, since 2020 (USD Million)
  • Table 28.185 Connected Drug Delivery Devices Market in Saudi Arabia, till 2035 (USD Million)
  • Table 28.186 Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, Historical Trends, since 2020 (USD Million)
  • Table 28.187 Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, till 2035 (USD Million)
  • Table 28.188 Connected Drug Delivery Devices Demand in Latin America and Rest of the World, Historical Trends, since 2020 (Million Units Sold)
  • Table 28.189 Connected Drug Delivery Devices Demand in Latin America and Rest of the World, till 2035 (Million Units Sold)
  • Table 28.190 Connected Drug Delivery Devices Market in Latin America and Rest of the World, Historical Trends, since 2020 (USD Million)
  • Table 28.191 Connected Drug Delivery Devices Market in Latin America and Rest of the World, till 2035 (USD Million)
  • Table 28.192 Connected Drug Delivery Devices Market in Brazil, Historical Trends, since 2020 (USD Million)
  • Table 28.193 Connected Drug Delivery Devices Market in Brazil, till 2035 (USD Million)
  • Table 28.194 Connected Drug Delivery Devices Market in Argentina, Historical Trends, since 2020 (USD Million)
  • Table 28.195 Connected Drug Delivery Devices Market in Argentina, till 2035 (USD Million)
  • Table 28.196 Connected Drug Delivery Devices Market in Rest of the World, Historical Trends, since 2020 (USD Million)
  • Table 28.197 Connected Drug Delivery Devices Market in Rest of the World, till 2035 (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 3.3 Market Dynamics: Robust Quality Control
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Connected / Smart Drug Delivery Devices Market Landscape
  • Figure 5.2 Executive Summary: Add-on Sensors Market Landscape
  • Figure 5.3 Executive Summary: Market Trends
  • Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 IoT Ecosystem: Different Components
  • Figure 6.2 Framework of Connected / Smart Drug Delivery Devices
  • Figure 6.3 Designing and Developing a Connected / Smart Drug Delivery Device: Key Considerations
  • Figure 6.4 Development of Connected Drug Delivery Devices: Stack Model
  • Figure 6.5 Connected / Smart Drug Delivery Device: Type of Technology Used
  • Figure 6.6 Advantages of Connected / Smart Drug Delivery Devices
  • Figure 7.1 Connected / Smart Drug Delivery Devices: Distribution by Stage of Development
  • Figure 7.2 Connected / Smart Drug Delivery Devices: Distribution by Launch Year
  • Figure 7.3 Connected / Smart Drug Delivery Devices: Distribution by Type of Integrated Device
  • Figure 7.4 Connected / Smart Drug Delivery Devices: Distribution by Route of Administration
  • Figure 7.5 Connected / Smart Drug Delivery Devices: Distribution by Therapeutic Area
  • Figure 7.6 Connected / Smart Drug Delivery Devices: Distribution by Target Indication
  • Figure 7.7 Connected / Smart Drug Delivery Devices: Distribution by Key Features
  • Figure 7.8 Connected / Smart Drug Delivery Devices: Distribution by Mode of Connectivity
  • Figure 7.9 Connected / Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
  • Figure 7.10 Connected / Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
  • Figure 7.11 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment
  • Figure 7.12 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size
  • Figure 7.13 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Location of Headquarters
  • Figure 7.14 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Year of Establishment and Location of Headquarters
  • Figure 7.15 Connected / Smart Drug Delivery Device Manufacturers: Distribution by Company Size and Location of Headquarters
  • Figure 7.16 Most Active Players: Distribution by Number of Connected / Smart Drug Delivery Devices Manufactured
  • Figure 8.1 Add-on Sensors: Distribution by Stage of Development
  • Figure 8.2 Add-on Sensors: Distribution by Launch Year
  • Figure 8.3 Add-on Sensors: Distribution by Compatible Device
  • Figure 8.4 Add-on Sensors: Distribution by Route of Administration
  • Figure 8.5 Add-on Sensors: Distribution by Therapeutic Area
  • Figure 8.6 Add-on Sensors: Distribution by Target Indication
  • Figure 8.7 Add-on Sensors: Distribution by Key Features
  • Figure 8.8 Add-on Sensors: Distribution by Mode of Connectivity
  • Figure 8.9 Add-on Sensors: Distribution by Availability of Companion Mobile Application
  • Figure 8.10 Add-on Sensors: Distribution by Availability of Data Storage / Cloud Platform
  • Figure 8.11 Add-on Sensor Manufacturers: Distribution by Year of Establishment
  • Figure 8.12 Add-on Sensor Manufacturers: Distribution by Company Size
  • Figure 8.13 Add-on Sensor Manufacturers: Distribution by Location of Headquarters
  • Figure 8.14 Add-on Sensor Manufacturers: Distribution by Year of Establishment and Location of Headquarters
  • Figure 8.15 Add-on Sensor Manufacturers: Distribution by Company Size and Location of Headquarters
  • Figure 8.16 Most Active Players: Distribution by Number of Add-on Sensors Manufactured
  • Figure 9.1 Product Competitiveness Analysis: Smart Handheld Injectors (Peer Group 1a)
  • Figure 9.2 Product Competitiveness Analysis: Smart Wearable Injectors (Peer Group 1b)
  • Figure 9.3 Product Competitiveness Analysis: Other Integrated Devices (Peer Group 1c)
  • Figure 9.4 Product Competitiveness Analysis: Add-on Sensors (Peer Group 2)
  • Figure 10.1 Medtronic: Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Figure 10.2 Insulet: Business Segment-wise Revenues and Consolidated Financial Details (USD Million)
  • Figure 10.3 Tandem Diabetes Care: Consolidated Financial Details (USD Million)
  • Figure 11.1 Gerresheimer: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)
  • Figure 11.2 Roche: Business Segment-wise Revenues and Consolidated Financial Details (CHF Billion)
  • Figure 11.3 Ypsomed: Business Segment-wise Revenues and Consolidated Financial Details (CHF Million)
  • Figure 13.1 Clinical Trial Analysis: Cumulative Year-wise Trend, till 2020
  • Figure 13.2 Clinical Trial Analysis: Year-wise Trend of Enrolled Patient Population by Trial Registration Year, till 2020
  • Figure 13.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 13.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 13.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status, till 2020
  • Figure 13.6 Clinical Trial Analysis: Distribution by Type of Device
  • Figure 13.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 13.8 Clinical Trial Analysis: Distribution of Number of Registered Trials by Therapeutic Area
  • Figure 13.9 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area
  • Figure 13.10 Clinical Trial Analysis: Distribution by Study Design
  • Figure 13.11 Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 13.12 Leading Connected / Smart Drug Delivery Devices and Add-On Sensors: Distribution by Number of Registered Trials
  • Figure 13.13 Clinical Trial Analysis: Distribution of Number of Registered Trials by Trial Status and Geography
  • Figure 13.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, till 2024
  • Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, till 2024
  • Figure 14.4 Partnerships and Collaborations: Distribution by Class of Device
  • Figure 14.5 Partnerships and Collaborations: Distribution by Type of Integrated Device
  • Figure 14.6 Partnerships and Collaborations: Distribution by Compatible Device
  • Figure 14.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 14.8 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Figure 14.9 Partnerships and Collaborations: Local and International Deals
  • Figure 15.1 Funding and Investments: Cumulative Year-wise Trend, till 2020
  • Figure 15.2 Funding and Investments: Distribution by Amount Invested, till 2020 (USD Million)
  • Figure 15.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
  • Figure 15.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 15.5 Distribution of Funding Instances by Year and Type of Funding, till 2020
  • Figure 15.6 Funding and Investments: Distribution of Funding Instances by Class of Device
  • Figure 15.7 Funding and Investments: Distribution of Funding Instances by Geography
  • Figure 15.8 Funding and Investments: Distribution of Funding Instances by Geography and Amount Invested (USD Million)
  • Figure 15.9 Most Active Players: Distribution by Number of Funding Instances
  • Figure 15.10 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 15.11 Leading Investors: Distribution by Number of Funding Instances
  • Figure 15.12 Summary of Funding and Investments, till 2020 (USD Million)
  • Figure 16.1 Connected / Smart Drug Delivery Devices: Value Chain
  • Figure 16.2 Cost Distribution Across Value Chain
  • Figure 16.3 Costs Associated with Concept Development and Proof of Concept
  • Figure 16.4 Costs Associated with Research and Product Development
  • Figure 16.5 Costs Associated with Clinical Trials
  • Figure 16.6 Costs Associated with Regulatory Approvals
  • Figure 16.7 Costs Associated with Manufacturing and Product Assembly
  • Figure 16.8 Costs Associated with Application Development
  • Figure 16.9 Costs Associated with Marketing and Sales
  • Figure 17.1 Global Regulations related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
  • Figure 17.2 USFDA: Approval Pathway for Combination Products
  • Figure 17.3 Health Canada: Approval Pathway for Combination Products
  • Figure 17.4 NMPA: Approval Pathway for Combination Products
  • Figure 17.5 Connected / Smart Drug Delivery Devices: Major Steps for Managing Privacy
  • Figure 18.1 Diabetes: Evolution of Drug Delivery / Connected Devices
  • Figure 18.2 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
  • Figure 18.3 Asthma: Evolution of Drug Delivery / Connected Devices
  • Figure 18.4 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthmatic Patients: Highlights on Twitter
  • Figure 19.1 Connected Drug Delivery Devices Market: SWOT Analysis
  • Figure 19.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 20.1 Global Connected Drug Delivery Devices Market, till 2035 (Million Units Sold, USD Million)
  • Figure 20.2 Global Connected Drug Delivery Devices Market, till 2035: Conservative Scenario (Million Units Sold, USD Million)
  • Figure 20.3 Global Connected Drug Delivery Devices Market, till 2035: Optimistic Scenario (Million Units Sold, USD Million)
  • Figure 21.1 Connected Drug Delivery Devices Market: Distribution by Type of Device, 2020, 2024 and 2035 (USD Million)
  • Figure 21.2 Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, till 2035 (Million Units Sold, USD Million)
  • Figure 21.3 Connected Drug Delivery Devices Market for Connected / Smart Inhalers, till 2035 (Million Units Sold, USD Million)
  • Figure 21.4 Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, till 2035 (Million Units Sold, USD Million)
  • Figure 21.5 Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, till 2035 (USD Million, Million Units Sold)
  • Figure 21.6 Connected Drug Delivery Devices Market for Connected / Smart Needle-free Injection Systems, till 2035 (USD Million, Million Units Sold)
  • Figure 22.1 Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity, 2020, 2024 and 2035 (USD Million)
  • Figure 22.2 Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, till 2035 (Million Units Sold, USD Million)
  • Figure 22.3 Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, till 2035 (Million Units Sold, USD Million)
  • Figure 22.4 Connected Drug Delivery Devices Market for Cellular-enabled Devices, till 2035 (Million Units Sold, USD Million)
  • Figure 22.5 Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, till 2035 (Million Units Sold, USD Million)
  • Figure 23.1 Connected Drug Delivery Devices Market: Distribution by Route of Administration, 2020, 2024 and 2035 (USD Million)
  • Figure 23.2 Connected Drug Delivery Devices Market for Parenteral Administration, till 2035 (Million Units Sold, USD Million)
  • Figure 23.3 Connected Drug Delivery Devices Market for Inhalational Administration, till 2035 (Million Units Sold, USD Million)
  • Figure 24.1 Connected Drug Delivery Devices Market: Distribution by Therapeutic Area, 2020, 2024 and 2035 (USD Million)
  • Figure 24.2 Connected Drug Delivery Devices Market for Metabolic Disorders, till 2035 (Million Units Sold, USD Million)
  • Figure 24.3 Connected Drug Delivery Devices Market for Respiratory Disorders, till 2035 (Million Units Sold, USD Million)
  • Figure 24.4 Connected Drug Delivery Devices Market for Autoimmune Disorders, till 2035 (Million Units Sold, USD Million)
  • Figure 24.5 Connected Drug Delivery Devices Market for Other Disorders, till 2035 (Million Units Sold, USD Million)
  • Figure 25.1 Connected Drug Delivery Devices Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
  • Figure 25.2 Connected Drug Delivery Devices Market in North America, till 2035 (Million Units Sold, USD Million)
  • Figure 25.3 Connected Drug Delivery Devices Market in the US, till 2035 (USD Million)
  • Figure 25.4 Connected Drug Delivery Devices Market in Canada, till 2035 (USD Million)
  • Figure 25.5 Connected Drug Delivery Devices Market in Europe, till 2035 (Million Units Sold, USD Million)
  • Figure 25.6 Connected Drug Delivery Devices Market in the UK, till 2035 (USD Million)
  • Figure 25.7 Connected Drug Delivery Devices Market in Germany, till 2035 (USD Million)
  • Figure 25.8 Connected Drug Delivery Devices Market in France, till 2035 (USD Million)
  • Figure 25.9 Connected Drug Delivery Devices Market in Italy, till 2035 (USD Million)
  • Figure 25.10 Connected Drug Delivery Devices Market in Spain, till 2035 (USD Million)
  • Figure 25.11 Connected Drug Delivery Devices Market in Rest of Europe, till 2035 (USD Million)
  • Figure 25.12 Connected Drug Delivery Devices Market in Asia-Pacific, till 2035 (Million Units Sold, USD Million)
  • Figure 25.13 Connected Drug Delivery Devices Market in China, till 2035 (USD Million)
  • Figure 25.14 Connected Drug Delivery Devices Market in India, till 2035 (USD Million)
  • Figure 25.15 Connected Drug Delivery Devices Market in Japan, till 2035 (USD Million)
  • Figure 25.16 Connected Drug Delivery Devices Market in Rest of Asia-Pacific, till 2035 (USD Million)
  • Figure 25.17 Connected Drug Delivery Devices Market in Middle East and North Africa, till 2035 (Million Units Sold, USD Million)
  • Figure 25.18 Connected Drug Delivery Devices Market in Egypt, till 2035 (USD Million)
  • Figure 25.19 Connected Drug Delivery Devices Market in Israel, till 2035 (USD Million)
  • Figure 25.20 Connected Drug Delivery Devices Market in Saudi Arabia, till 2035 (USD Million)
  • Figure 25.21 Connected Drug Delivery Devices Market in Rest of Middle East and North Africa, till 2035 (USD Million)
  • Figure 25.22 Connected Drug Delivery Devices Market in Latin America and Rest of the World, till 2035 (Million Units Sold, USD Million)
  • Figure 25.23 Connected Drug Delivery Devices Market in Brazil, till 2035 (USD Million)
  • Figure 25.24 Connected Drug Delivery Devices Market in Argentina, till 2035 (USD Million)
  • Figure 25.25 Connected Drug Delivery Devices Market in Rest of the World, till 2035 (USD Million)
  • Figure 26.1 Concluding Remarks: Connected Drug Delivery Devices Market Landscape
  • Figure 26.2 Concluding Remarks: Add-on-Sensors Market Landscape
  • Figure 26.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 26.4 Concluding Remarks: Funding and Investments
  • Figure 26.5 Concluding Remarks: Market Sizing and Opportunity Analysis